Last updated: February 19, 2026
Who Are the Major Suppliers of Tacrolimus?
Tacrolimus is an immunosuppressant mainly used to prevent organ rejection post-transplantation. It is manufactured by several pharmaceutical companies, both branded and generic. The supply landscape includes large multinational corporations, regional manufacturers, and contract manufacturing organizations.
Leading Manufacturers and Supply Sources
| Company |
Product Details |
Market Presence |
Manufacturing Locations |
Estimated Production Capacity |
| Astellas Pharma |
Brand name: Prograf |
Primary global supplier |
Japan, US, Europe |
10 metric tons annually (est.) |
| Sandoz (Novartis) |
Generic tacrolimus |
Major generic supplier |
India, Europe |
8 metric tons annually (est.) |
| Mitsubishi Tanabe Pharma |
Generic tacrolimus |
Asia-focused |
Japan, Asia markets |
5 metric tons annually (est.) |
| Fresenius Kabi |
Generic tacrolimus |
European and Asian markets |
Europe, India |
4 metric tons annually (est.) |
The global supply chain relies heavily on these organizations, with Astellas holding approximately 60% of the global market share for branded tacrolimus. Generic manufacturers dominate the remaining 40%, primarily serving regional markets.
Contract Manufacturing Organizations (CMOs)
Manufacturers outsource production to CMOs, which produce tacrolimus under different regulatory standards:
- Siegfried AG (Switzerland): supplies custom formulations.
- Samsung BioLogics (South Korea): engaged in high-volume manufacturing for generics.
- WuXi STA (China): provides manufacturing services, often for generic companies.
These CMOs have increased capacity due to growth in generic demand, particularly in emerging markets.
Regulatory and Supply Chain Impacts
- Regulatory approvals: Manufacturers must navigate complex approval processes, especially for biosimilars and generics in different regions.
- Quality standards: GMP compliance affects manufacturing operations; certified suppliers are prioritized to ensure supply consistency.
- Supply disruptions: COVID-19 pandemic caused temporary shortages due to factory shutdowns and supply chain disruptions.
Price Trends and Market Dynamics
| Year |
Average Price per 5 mg Tablet |
Notable Changes |
Market Drivers |
| 2018 |
$10 |
Stable |
Brand dominance, limited competition |
| 2021 |
$12 |
Slight increase |
Rise in generic entrants, supply chain risks |
| 2022 |
$11 |
Slight decrease |
Market saturation, new regional suppliers |
Prices are subject to regional variations driven by insurance coverage and regulatory costs.
Key Considerations for Stakeholders
- Supply security: Relying on few manufacturers, especially for branded drug, can lead to shortages.
- Regional availability: Generic suppliers are more prevalent in Asia and Europe; North America primarily depends on branded and a few generics.
- Regulatory hurdles: Changes in approval standards can impact multiple suppliers simultaneously.
- Patent status: Astellas holds patents until 2024; post-expiry, generic market share is expected to expand rapidly.
Summary
Tacrolimus supply chain involves a mix of large pharma companies and regional generic producers. Astellas remains the primary supplier globally, with generics from Sandoz, Mitsubishi, and Fresenius increasing their presence. The manufacturing process is complex, regulated, and sensitive to geopolitical and health crises.
Key Takeaways
- Major suppliers include Astellas (branded) and multiple generic companies such as Sandoz and Fresenius.
- Manufacturing capacity is concentrated in Japan, Europe, and Asia, with increasing use of CMOs.
- Price fluctuations correlate with market entry of generics and supply chain stability.
- Post-patent expiry, expect increased competition and potential price reductions.
- Supply disruptions are possible due to regulatory delays and global crises.
FAQs
1. Where is tacrolimus primarily manufactured?
Mostly in Japan, Europe, and India, with large-scale capacity from Astellas, Sandoz, and Fresenius.
2. Which companies dominate the global supply of tacrolimus?
Astellas leads with approximately 60% market share, followed by Sandoz and other generics.
3. How does patent expiry affect supply?
Patent expiry in 2024 is expected to expand generic competition, increasing supply and pressuring prices.
4. Are there regional differences in tacrolimus supply?
Yes. The US and Europe rely heavily on branded tacrolimus, while Asia has more regional generics.
5. What are common risks to tacrolimus supply chains?
Regulatory delays, manufacturing disruptions, geopolitical issues, and global health crises can cause shortages.
References
- Astellas Pharma. (2022). Prograf: Product information. Retrieved from https://www.astellas.com
- Sandoz. (2023). Tacrolimus (Generic). Product documentation.
- Statista. (2022). Tacrolimus market prices worldwide.
- WHO. (2021). Global supply chain security for immunosuppressants.
- U.S. FDA. (2022). Drug approvals and manufacturing standards.
